Treatment of Inflammatory Bowel Disease with Biologics
216 Non-melanoma Skin Cancer In the USA, NMSC is the most commonly diagnosed malignancy. NMSC includes both squamous cell carcin ...
217 colorectal cancer. There was an increased risk of NMSC with thiopurine treatment for >3 years, and secondary analysis-dem ...
218 Melanoma In the USA, melanoma is the fifth most common cancer for men and the seventh most common cancer for women. It is re ...
219 Unlike the data on NMSC where the risk may be mediated through alternate concomitant medications (such as thiopurines), anti ...
220 The risk of lymphoma in patients on anti-TNFs has also been evaluated in the RA population, where thiopurine use is less com ...
221 TNF-alpha inhibitor alone (1 case) [ 30 ]. This again echoes the concern for potenti- ated risk of HTCL with joint anti-TNF ...
222 ability clear human papilloma virus (HPV) infections [ 36 ]. Kane et al. conducted a case-control study evaluating 40 patien ...
223 Use of Anti-TNFs in Patients with a Prior History of Malignancy The safety of anti-TNF therapy in patients with a history of ...
224 decisions. For example, reporting the relative risk without also reporting the abso- lute risk can skew a patient’s percepti ...
225 anti-TNF agents. Such examinations are recommended in posttransplant popula- tions where risk is also higher. Finally, terti ...
226 is in favor of benefit at the population level. Risks seem to be focused in three main groups: skin cancer, cervical dysplas ...
227 References Weinberg JM, Buchholz R. TNF-alpha inhibitors. Basel; Boston: Birkhäuser Verlag; 2006. Van Deventer SJ. Tumour n ...
228 de La Forest DM, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: a systematic literature r ...
229 van Schaik FD, van Oijen MG, Smeets HM, et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflamma ...
© Springer International Publishing AG 2018 231 A.S. Cheifetz, J.D. Feuerstein (eds.), Treatment of Inflammatory Bowel Disease w ...
232 Infusion and Injection Site Reactions Clinical Presentation Infusion reactions, both acute and delayed types, are defined as ...
233 consisting of 86 adults and pediatric patients receiving episodic infliximab retreat- ment, Kugathasan et al. found that a d ...
234 the biologic agent is administered again, it binds to these antibodies, causing rapid release of histamine and other mediato ...
235 Antibody testing, checking for isotypes IgG and IgE, is another way to risk- stratify patients after an episode of infusion ...
236 In general, patients who develop severe infusion or injection reactions are rec- ommended to change therapy to another agent ...
«
7
8
9
10
11
12
13
14
15
16
»
Free download pdf